Detalhe da pesquisa
1.
A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.
J Neurooncol
; 126(2): 309-16, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26508094